Cognitive assessment in diverse populations: implications for Alzheimer’s disease clinical trials

By 2060, racially/ethnically diverse individuals will constitute almost half of all older adults in the US and experience largest increases in dementia burden. Appropriate representation of diverse participants in clinical trials is critical to ensure generalizability of outcomes. Screening/inclusion criteria for trials often involve a brief cognitive assessment to indicate overall disease severity. We examined the Mini‐Mental State Examination (MMSE), the most widely used assessment, as a recruitment tool in diverse older adults.